Progress of research on pathogenesis and therapeutic targets of autosomal dominant polycystic kidney disease

doi:10.3877/cma.j.issn.2095-3216.2017.01.008

Abstract

Abstract:

Autosomal dominant polycystic kidney disease (ADPKD) is a common inherited kidney disease, which is characterized by bilateral renal multiple fluid-filled cysts. ADPKD is the fourth cause of uremia, with a prevalence of about 1/1 000. Approximately half of the patients with ADPKD will progress to end-stage renal disease before the age of 60 years, but there has been not any very effective therapies. In recent years, advances in the molecular mechanisms of this disease have provided new directions for seeking the therapeutic targets. Preclinical models and clinical trials of the novel therapies have achieved positive results. This review focused on the progress of studies on pathogenesis and therapies of ADPKD.

Key words: Autosomal dominant polycystic kidney disease, Pathogenesis, Therapy

Man Chen, Yuansheng Xie. Progress of research on pathogenesis and therapeutic targets of autosomal dominant polycystic kidney disease[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2017, 06(01): 34-38.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3216.2017.01.008

https://zhsbyjdzzz.cma-cmc.com.cn/EN/Y2017/V06/I01/34

Figures/Tables 1

References 58

[1]	Simms RJ. Autosomal dominant polycystic kidney disease [J]. BMJ, 2016, 352: i679.
[2]	The European Polycystic Kidney Disease Consortium. The polycystic kidney disease 1 gene encodes a 14 kb transcript and lies within a duplicated region on chromosome 16 [J]. Cell, 1994, 78(4): 725.
[3]	Mochizuki T, Wu G, Hayashi T, et al. PKD2, a gene for polycystic kidney disease that encodes an integral membrane protein [J]. Science, 1996, 272(5266): 1339-1342.
[4]	Jin M, Xie Y, Chen Z, et al. System analysis of gene mutations and clinical phenotype in Chinese patients with autosomal-dominant polycystic kidney disease [J]. Sci Rep, 2016, 6: 35945.
[5]	Nauli SM, Alenghat FJ, Luo Y, et al. Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells [J]. Nat Genet, 2003, 33(2): 129-137.
[6]	Aguilar A. Polycystic kidney disease: PC2 function: insights from the cold [J]. Nat Rev Nephrol, 2017, 13(3): 136.
[7]	Bankir L, Bichet DG. Polycystic kidney disease: An early urea-selective urine-concentrating defect in ADPKD [J]. Nat Rev Nephrol, 2012，8(8): 437-439.
[8]	Torres VE, Harris PC. Strategies targeting cAMP signaling in the treatment of polycystic kidney disease [J]. J Am Soc Nephrol, 2014, 25(1): 18-32.
[9]	Harris PC, Torres VE. Genetic mechanisms and signaling pathways in autosomal dominant polycystic kidney disease [J]. J Clin Invest, 2014, 124(6): 2315-2324.
[10]	Wu G, D′Agati V, Cai Y, et al. Somatic inactivation of Pkd2 results in polycystic kidney disease [J]. Cell, 1998, 93(2): 177-188.
[11]	Hopp K, Ward CJ, Hommerding CJ, et al. Functional polycystin-1 dosage governs autosomal dominant polycystic kidney disease severity [J]. J Clin Invest, 2012, 122(11): 4257-4273.
[12]	Piontek K, Menezes LF, Garcia-Gonzalez MA, et al. A critical developmental switch defines the kinetics of kidney cyst formation after loss of Pkd1 [J]. Nat Med, 2007, 13(12): 1490-1495.
[13]	Rowe I, Chiaravalli M, Mannella V, et al. Defective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategy [J]. Nat Med, 2013, 19(4): 488-493.
[14]	Werder AA, Amos MA, Nielsen AH, et al. Comparative effects of germfree and ambient environments on the development of cystic kidney disease in CFWwd mice [J]. J Lab Clin Med, 1984, 103(3): 399-407.
[15]	Gardner KD Jr, Burnside JS, Elzinga LW, et al. Cytokines in fluids from polycystic kidneys [J]. Kidney Int, 1991, 39(4): 718-724.
[16]	Leuenroth SJ, Bencivenga N, Igarashi P, et al. Triptolide reduces cystogenesis in a model of ADPKD [J]. J Am Soc Nephrol, 2008, 19(9): 1659-1662.
[17]	Chen D, Ma Y, Wang X, et al. Triptolide-containing formulation in patients with autosomal dominant polycystic kidney disease and proteinuria: an uncontrolled trial [J]. Am J Kidney Dis, 2014, 63(6): 1070-1072.
[18]	Grantham JJ, Chapman AB, Blais J, et al. Tolvaptan suppresses monocyte chemotactic protein-1 excretion in autosomal-dominant polycystic kidney disease [J]. Nephrol Dial Transplant, 2016, [Epub ahead of print]．
[19]	Gattone VH 2nd, Wang X, Harris PC, et al. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist [J]. Nat Med, 2003, 9(10): 1323-1326.
[20]	Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease [J]. N Engl J Med, 2012, 367(25): 2407-2418.
[21]	Erickson KF, Chertow GM, Goldhaber-Fiebert JD. Cost-effectiveness of tolvaptan in autosomal dominant polycystic kidney disease [J]. Ann Intern Med, 2013, 159(6): 382-389.
[22]	Torres VE, Devuyst O, Chapman AB, et al. Rationale and design of a clinical trial investigating tolvaptan safety and efficacy in autosomal dominant polycystic kidney disease [J]. Am J Nephrol, 2017, 45(3): 257-266.
[23]	Masyuk TV, Radtke BN, Stroope AJ, et al. Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases [J]. Hepatology, 2013, 58(1): 409-421.
[24]	Caroli A, Perico N, Perna A, et al. Effect of long acting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial [J]. Lancet, 2013, 382(9903): 1485-1495.
[25]	Hopp K, Hommerding CJ, Wang X, et al. Tolvaptan plus pasireotide shows enhanced efficacy in a PKD1 model [J]. J Am Soc Nephrol, 2015, 26(1): 39-47.
[26]	Sweeney WE Jr, von Vigier RO, Frost P, et al. Src inhibition ameliorates polycystic kidney disease [J]. J Am Soc Nephrol, 2008, 19(7): 1331-1341.
[27]	Elliott J, Zheleznova NN, Wilson PD. c-Src inactivation reduces renal epithelial cell-matrix adhesion, proliferation, and cyst formation [J]. Am J Physiol Cell Physiol, 2011, 301(2): C522-C529.
[28]	Yamaguchi T, Reif GA, Calvet JP, et al. Sorafenib inhibits cAMP-dependent ERK activation, cell proliferation, and in vitro cyst growth of human ADPKD cyst epithelial cells [J]. Am J Physiol Renal Physiol, 2010, 299(5): F944-F951.
[29]	Tao Y, Kim J, Schrier RW, et al. Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease [J]. J Am Soc Nephrol, 2005, 16(1): 46-51.
[30]	Xue C, Dai B, Mei C. Long-term treatment with mammalian target of rapamycin inhibitor does not benefit patients with autosomal dominant polycystic kidney disease: a meta-analysis [J]. Nephron Clin Pract, 2013, 124(1-2): 10-16.
[31]	Novalic Z, van der Wal AM, Leonhard WN, et al. Dose-dependent effects of sirolimus on mTOR signaling and polycystic kidney disease [J]. J Am Soc Nephrol, 2012, 23(5): 842-853.
[32]	Shillingford JM, Leamon CP, Vlahov IR, et al. Folate-conjugated rapamycin slows progression of polycystic kidney disease [J]. J Am Soc Nephrol, 2012, 23(10): 1674-1681.
[33]	Ravichandran K, Zafar I, He Z, et al. An mTOR anti-sense oligonucleotide decreases polycystic kidney disease in mice with a targeted mutation in Pkd2 [J]. Hum Mol Genet, 2014, 23(18): 4919-4931.
[34]	Zhu P, Sieben CJ, Xu X, et al. Autophagy activators suppress cystogenesis in an autosomal dominant polycystic kidney disease model [J]. Hum Mol Genet, 2016, [Epub ahead of print]．
[35]	Rowe I, Boletta A. Defective metabolism in polycystic kidney disease: potential for therapy and open questions [J]. Nephrol Dial Transplant, 2014, 29(8): 1480-1486.
[36]	Riwanto M, Kapoor S, Rodriguez D, et al. Inhibition of aerobic glycolysis attenuates disease progression in polycystic kidney disease [J]. PLoS One, 2016, 11(1): e0146654.
[37]	Hallows KR, Raghuram V, Kemp BE, et al. Inhibition of cystic fibrosis transmembrane conductance regulator by novel interaction with the metabolic sensor AMP-activated protein kinase [J]. J Clin Invest, 2000, 105(12): 1711-1721.
[38]	Inoki K, Zhu T, Guan KL. TSC2 mediates cellular energy response to control cell growth and survival [J]. Cell, 2003, 115(5): 577-590.
[39]	Takiar V, Nishio S, Seo-Mayer P, et al. Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis [J]. Proc Natl Acad Sci USA, 2011, 108(6): 2462-2467.
[40]	Warner G, Hein KZ, Nin V, et al. Food restriction ameliorates the development of polycystic kidney disease [J]. J Am Soc Nephrol, 2016, 27(5): 1437-1447.
[41]	Kipp KR, Rezaei M, Lin L, et al. A mild reduction of food intake slows disease progression in an orthologous mouse model of polycystic kidney disease [J]. Am J Physiol Renal Physiol, 2016, [Epub ahead of print]．
[42]	Weimbs T, Olsan EE, Talbot JJ. Regulation of STATs by polycystin-1 and their role in polycystic kidney disease [J]. JAKSTAT, 2013, 2(2): e23650.
[43]	Takakura A, Nelson EA, Haque N, et al. Pyrimethamine inhibits adult polycystic kidney disease by modulating STAT signaling pathways [J]. Hum Mol Genet, 2011, 20(21): 4143-4154.
[44]	Fragiadaki M, Lannoy M, Themanns M, et al. STAT5 drives abnormal proliferation in autosomal dominant polycystic kidney disease [J]. Kidney Int, 2017, 91(3): 575-586.
[45]	Li X, Magenheimer BS, Xia S, et al. A tumor necrosis factor-alpha-mediated pathway promoting autosomal dominant polycystic kidney disease [J]. Nat Med, 2008, 14(8): 863-868.
[46]	Zhou JX, Fan LX, Li X, et al. TNFalpha signaling regulates cystic epithelial cell proliferation through Akt/mTOR and ERK/MAPK/Cdk2 mediated Id2 signaling [J]. PLoS One, 2015, 10(6): e0131043.
[47]	Wu M, Gu J, Mei S, et al. Resveratrol delays polycystic kidney disease progression through attenuation of nuclear factor kappaB-induced inflammation [J]. Nephrol Dial Transplant, 2016, 31(11): 1826-1834.
[48]	Chen L, Zhou X, Fan LX, et al. Macrophage migration inhibitory factor promotes cyst growth in polycystic kidney disease [J]. J Clin Invest, 2015, 125(6): 2399-2412.
[49]	Karihaloo A, Koraishy F, Huen SC, et al. Macrophages promote cyst growth in polycystic kidney disease [J]. J Am Soc Nephrol, 2011, 22(10): 1809-1814.
[50]	Torres VE, Abebe KZ, Chapman AB, et al. Angiotensin blockade in late autosomal dominant polycystic kidney disease [J]. N Engl J Med, 2014, 371(24): 2267-2276.
[51]	Schrier RW, Abebe KZ, Perrone RD, et al. Blood pressure in early autosomal dominant polycystic kidney disease [J]. N Engl J Med, 2014, 371(24): 2255-2266.
[52]	Saigusa T, Dang Y, Mullick AE, et al. Suppressing angiotensinogen synthesis attenuates kidney cyst formation in a Pkd1 mouse model [J]. FASEB J, 2016, 30(1): 370-379.
[53]	Xia S, Li X, Johnson T, et al. Polycystin-dependent fluid flow sensing targets histone deacetylase 5 to prevent the development of renal cysts [J]. Development, 2010, 137(7): 1075-1084.
[54]	Li X. Epigenetics and autosomal dominant polycystic kidney disease [J]. Biochim Biophys Acta, 2011, 1812(10): 1213-1218.
[55]	Zhou X, Fan LX, Sweeney WE Jr, et al. Sirtuin 1 inhibition delays cyst formation in autosomal-dominant polycystic kidney disease [J]. J Clin Invest, 2013, 123(7): 3084-3098.
[56]	van Dijk MA, Kamper AM, van Veen S, et al. Effect of simvastatin on renal function in autosomal dominant polycystic kidney disease [J]. Nephrol Dial Transplant, 2001, 16(11): 2152-2157.
[57]	Cadnapaphornchai MA, George DM, McFann K, et al. Effect of pravastatin on total kidney volume, left ventricular mass index, and microalbuminuria in pediatric autosomal dominant polycystic kidney disease [J]. Clin J Am Soc Nephrol, 2014, 9(5): 889-896.
[58]	Klawitter J, McFann K, Pennington AT, et al. Pravastatin therapy and biomarker changes in children and young adults with autosomal dominant polycystic kidney disease [J]. Clin J Am Soc Nephrol, 2015, 10(9): 1534-1541.

Please choose a citation manager

Content to export